trending Market Intelligence /marketintelligence/en/news-insights/trending/1LLELWSQuDhMZtmdST1z3Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Ardian to take control of Swiss drugmaker Sintetica

Blog

Banking Essentials Newsletter: May Edition

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

Latin American and Caribbean Market Considerations Blog Series: Focus on IFRS 9


Ardian to take control of Swiss drugmaker Sintetica

Global private investment house Ardian agreed to acquire a majority stake in Swiss pharmaceutical company Sintetica SA Pharmaceuticals.

Sintetica's current stockholders will reinvest in the company and retain a minority stake.

Sintetica, which specializes in the research, manufacturing and marketing of anesthetics, analgesics, adrenergic agonists and other sterile injectable solutions, will pursue global expansion through the new partnership with Ardian.

Separately, an investor group including Ardian and Horizon Capital is selling British food and drink retailer EAT Ltd. to food shop operator Pret A Manger (Europe) Ltd.

Pret A Manger said in a release that it intends to convert most of EAT's shops to Veggie Prets to meet the rising consumer demand for more High Street vegetarian and vegan options.